The incumbent is expected to and will have resources and personnel support to conduct clinical and translational research related to liver disease. The incumbent will be a faculty member of the NIH Clinical Center hepatology/gastroenterology inpatient, outpatient and consultation services and take a leadership role in training and supervising fellows and rotating residents and students. The incumbent will work as a member of a dynamic clinical team consisting of other faculty, fellows, other trainees and research nurses. The position requires excellent clinical hepatology and gastroenterology skills. The LDB of NIDDK is located on the main campus of the NIH in Bethesda, Maryland.
The NIDDK Intramural Research Program provides extensive opportunities for collaboration with the diverse and dynamic medical community at NIH, mostly located on the Bethesda campus. The NIH Clinical Research Center, with 200 beds, and outpatient clinics, provides care exclusively to patients who are participating in clinical trials. Extensive training opportunities in clinical research are available, including a Master’s of Health Science program run jointly by NIH and Duke University. In addition to full federal benefits, salary is commensurate with experience and accomplishments in the range of 200K’s. The incumbent will be eligible for relocation expense and NIH loan repayment program. Applications from women, minorities and persons with disabilities are strongly encouraged.
The candidate must be a US citizen or permanent resident, hold a US medical license, and be ABIM board-eligible in Gastroenterology and Hepatology. Qualified individuals should send a cover letter (one-page) describing research experience and interests, curriculum vitae, bibliography, and contact information for three references to:
About National Institute of Diabetes and Digestive and Kidney Diseases
The liver performs many critical metabolic functions, including processing and distribution of nutrients. Liver diseases can be caused by infection, such as hepatitis B and C, or by genetic mutations. Other liver diseases can be triggered by autoimmune reactions or drug toxicity. The rise in obesity in the United States has led to a rise in nonalcoholic fatty liver disease. Many liver diseases place individuals at higher risk for developing liver cancer. The only current treatment for end-stage liver disease is a liver transplant, and the number of livers available from deceased donors is limited. Thus NIDDK-supported liver research focuses on identifying liver disease early, preserving liver function in people with liver disease, and developing new treatment options, including transplants performed with liver tissue from living donors.Other NIDDK-funded research is investigating the role gut microbes may play in the progression of nonalcoholic fatty liver disease, and in understanding how the body’s natural killer T cells can activate an immune response to hepatitis B.In a collaborative effort with the National Library of Medicine, NIDDK has developed LiverTox ?, an online resourc...e for drug-induced liver injury, providing a “living textbook” with hundreds of case reports, patient information, and a database of over a thousand drugs and supplements.In addition, NIDDK responds to questions and provides health information about liver disease to people with liver disease and to their families, health professionals, and the public.